JOHN R. HORN, PHARM.D., FCCP
`
`Department of Pharmacy
`University of Washington
`Box 357630
`Seattle, WA 98195
`jrhorn@uw.edu
`
`Academic Appointments
`1994 - Present Professor of Pharmacy, Department of Pharmacy, University of
`Washington, School of Pharmacy.
`1984 - 1994 Associate Professor of Pharmacy, Department of Pharmacy, University of
`Washington, School of Pharmacy.
`1977 - l984 Assistant Professor of Pharmacy, Department of Pharmacy, University of
`Washington, School of Pharmacy.
`1976 - 1977 Instructor of Pharmacology, University of Cincinnati College of Nursing
`and Health.
`1974 - 1977 Instructor of Clinical Pharmacy, University of Cincinnati Medical Center,
`College of Pharmacy, Cincinnati, OH.
`1973 - 1977 Research Associate, University of Cincinnati, Raymond Walters Branch,
`Cincinnati, OH.
`
`Administrative Appointments
`1985 - Present Associate Director, University of Washington Medical Center Pharmacy
`Department.
`1993 - 1997 Vice Chairman, Department of Pharmacy, School of Pharmacy, University
`of Washington.
`1988 - 1997 Director, Doctor of Pharmacy Program, Department of Pharmacy,
`University of Washington, School of Pharmacy.
`
`Professional Experience
`1991 - 1994 Attending Pharmacy Preceptor, Internal Medicine Service, University of
`Washington Medical Center.
`1982 - 1991 Clinical Pharmacist, Internal Medicine, University of Washington Medical
`Center.
`1981 - 1982 Residency Coordinator, Virginia Mason Hospital Pharmacy Department.
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`1978 - 1982 Affiliate Member, Virginia Mason Research Center.
`1977 - 1982 Clinical Coordinator, Virginia Mason Hospital Pharmacy Department.
`1973 - 1977 Director of Pharmacy Education, Medicine Unit One, University of
`Cincinnati Medical Center, Cincinnati General Hospital.
`1972 - 1973 Assistant Clinical Pharmacist, Washington State University, Deaconess
`Hospital, Spokane, WA.
`1972 - 1973 Pharmacist, Valu-Mart Stores, Inc., Spokane, WA, and Whitworth
`Pharmacy, Spokane, WA.
`1970 - 1972 Pharmacy Intern, North Hill Drug Company, Spokane, WA, Memorial
`Hospital, Pullman, WA, Whitlock's Prescription Pharmacy, Spokane, WA.
`
`Education
`1977 Doctor of Pharmacy, University of Cincinnati, Cincinnati, Ohio.
`1973 Clinical Pharmacy Residency, Deaconess Hospital, Spokane, Washington.
`1972 Bachelors of Pharmacy, Washington State University, Pullman, Washington.
`
`Organizations, Awards, Honors
`Distinguished Alumnus Award, University of Cincinnati College of Pharmacy.
`Distinguished Practitioner, National Academies of Practice in Pharmacy
`Member, Institute of Translational Health Sciences
`Drug Therapy Research Award for Cyclosporine-drug interactions and the influence of
`patient age, American Society of Health-System Pharmacists Research and Education
`Foundation.
`Fellow, American College of Clinical Pharmacy
`American Society of Health-Systems Pharmacists
`American College of Clinical Pharmacy
`Washington State Pharmacists Association
`Past President, Seattle Area Society of Hospital Pharmacists
`Kappa Psi Pharmaceutical Fraternity
`SAPhA; officer, delegate to SAPhA Interdisciplinary Health Manpower Conference,
`chairman of Drug Abuse Committee
`Recipient of Kappa Psi and Health Sciences Scholarships
`Recipient of Upjohn Achievement Award
`
`
`Committee Assignments
`
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`University of Washington, School of Pharmacy
`
`
`Department of Pharmacy Merit Review Committee
`
`2015
`Department of Pharmacy Faculty Activity Report Committee
`
`2014
`Plein Endowed Fund Selection Committee - Chairman
`2012 – 2015
`Doctor of Pharmacy Recruitment Committee
`2011 – 2015
`Clinical and Affiliate Faculty Review Committee
`2007 – 2015
`Faculty Council
`2004 – 2007
`Plein Endowed Fund Selection Committee
`2004 – 2007
`Ad hoc School of Pharmacy Promotion and Tenure
`2003 – 2005
`Executive Committee
`2002 – 2005
`Ad hoc Department of Pharmacy Promotion and Tenure, Chairman
`2001 – 2005
`Department of Pharmacy Continuing Education
`
`
`1993 – 2003
`Committee
`
`
`
`External Doctor of Pharmacy Advisory Board
`2000 – 2003
`Member Curriculum Committee
`1999 – 2000
`Faculty representative to University Senate
`1999 – 2000
`Chair, Curriculum Committee
`1998 – 1999
`Promotions and Tenure Committee
`1996 – 1999
`Chairman Health Sciences Open House Pharmacy Exhibit
`1997
`
`Committee
`
`
`
`Curriculum Committee
`1997 – 1998
`Doctor of Pharmacy Program Committee
`1992 – 1997
`Chairman Doctor of Pharmacy Committee
`1988 – 1997
`Chairman, External Doctor of Pharmacy Committee
`1992 – 1996
`School of Pharmacy Faculty Council Representative
`1992 – 1995
`Faculty Promotion and Tenure Guidelines Committee
`1993 – 1994
`Chairman Pharmacy Career Day Committee
`1991 – 1994
`1983, 1985 – 1988 Doctor of Pharmacy Committee
`1982 – 1985
`Curriculum Committee
`1981 – 1982
`Graduate Studies Committee
`1980 – 1981
`Student Advising Committee
`
`
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`1977 – 1978
`1977 – Present
`
`
`
`
`
`Graduate Admissions Committee
`Chairman and member, Various Faculty Search
`Committees
`
`
`
`
`
`University of Washington Medical Center
`1986 - Present
`Ad Hoc University of Washington Human Subjects Review
`Committee
`Drug Interactions Task Force
`Pharmacy and Therapeutics Committee
`Scientific Advisory Committee, Clinical Research Center
`Recruiting and Retaining the Highest Quality Staff Subcommittee
`Associate Director Search Committee
`Department of Pharmacy Residency Transition Committee
`Associate Director Search Committee
`University of Washington Human Subjects Review Committee
`American Healthcare Systems Bioequivalence Review Committee
`
`2008 - Present
`1985 - Present
`1987 - 2006
`2002
`2000 - 2001
`1993 - 1994
`1993 - 1994
`1980 - 1982
`1986 - 1991
`
`
`Virginia Mason Medical Center, Seattle
`
`Clinical Pharmacology Unit Advisory Board
`Experimental Pharmacology Program Committee
`Pharmacy and Therapeutics Committee
`Virginia Mason Research Center Affiliate Member
`Long Range Planning Committee, Virginia Mason Research Center
`Human Subjects Review Committee
`
`
`1981 - 1982
`1979 - 1982
`1979 - 1982
`1979 - 1982
`1979 - 1980
`1978 - 1982
`
`
`Admissions Committee, Recruitment Committee, Student Affairs Committee
`
`
`University of Cincinnati, College of Pharmacy, Cincinnati
`
`National Healthcare Organizations:
`
`American College of Clinical Pharmacy
`Present
`
`Abstract Reviewer, Annual Meeting
`2009
`
`Best Poster Award Reviewer, 2009 Annual Meeting
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`Best Poster Award Reviewer, 2007 Annual Meeting
`Best Poster Award Reviewer, 2004 Annual Meeting
`Best Poster Award Reviewer, 2002 Spring Forum
`Research Fellowship Reviewer
`Budget and Finance Committee
`Budget and Finance Committee
`Research Institute Reviewer
`Budget and Finance Committee
`Chairman, Awards Committee
`Advisory Committee on Pharmacoeconomics and Outcomes
`Curriculum
`Research Institute Reviewer
`Academic Affairs Committee
`Research Institute Reviewer
`Program Committee
`Budget and Finance Committee
`
`
`2007
`
`2004
`
`2002
`1992 - 2001
`1999
`
`1998
`
`1998
`
`1998
`
`1997
`
`1995
`
`
`
`
`1994
`
`1994 - 1995
`1992
`
`1991 - 1992
`1989 - 1990
`
`American Society of Health-Systems Pharmacists
`2012-2014
`
`ASHP Section of Pharmacy Informatics and Technology Advisory
`Group on Clinical Information Systems
`2009-2012
`
`ASHP Section of Pharmacy Informatics and Technology Advisory
`Group on Ambulatory Care Informatics
`2007-2009
`
`ASHP Section of Pharmacy Informatics and Technology Advisory
`Group on Clinical Information Systems
`
`American Association of Colleges of Pharmacy
`1984 - 1985 and
`1987 - 1988
`1987
`
`1985
`
`
`Faculty Delegate
`Research and Graduate Affairs Committee
`Nominations Committee
`
`
`
`World Gastroenterology Organization
`2012- 2013 - Member of the 2012 World Digestive Health Day Steering Committee
`2013-2015 – Member of the WGO Global Guidelines Committee
`
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`
`
`Pharmacy Quality Alliance
`2014-2015 - Member of the Drug-Drug-Interaction Expert Panel to update the PQA DDI
`performance measure
`
`Chair, Drug Interactions Specialty Panel, The Annals of
`
`Pharmacotherapy The Journal of Human Pharmacology and Drug
`
`Co-Author and Co-Editor: Drug Interactions Updates, Facts and
`
`Editorial Board
`
`2006 – Present
`Pharmacotherapy
`2003 – Present
`Therapy
`1999 - Present
`Comparisons, Inc.
`Co-Author and Co-Editor: Drug Interactions Newsletter and
`1985 – 1998
`Updates, Applied Therapeutics, Inc.
`1987 – 1990
`Co-Editor, The Hansten Drug Interaction Knowledge Base
`Program, Lea & Febiger, Inc.
`1982 – 1983
`Co-Editor, Drug Therapy Topics, University of Washington Medical
`Center Department of Pharmacy and Drug Information Service
`1980 – 1985
`Chairman, General Medicine Specialty Panel, Drug Intelligence and
`Clinical Pharmacy
`Editor, Pharmacy NewsCapsule, Virginia Mason Pharmacy
`1978 – 1982
`Department Newsletter on Drugs and Therapeutics
`1977 – 1991
`Member, Editorial Council, Drug Intelligence and Clinical
`Pharmacy, Annals of Pharmacotherapy
`
`Reviewer
`Journal of Clinical Pharmacology
`American Journal of Health-System Pharmacists
`The Annals of Pharmacotherapy
`Pharmacotherapy
`
`
`Publications
`
`Books
`2000 to 2015, updated quarterly, Hansten and Horn’s Drug Interactions Analysis and
`Management (Loose Leaf), Philip Hansten and John Horn, Facts and Comparisons, Inc.
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`2015 The Top 100 Drug Interactions: A Guide to Patient Management, 2015 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2014 Drug Interactions Analysis and Management (Bound), Philip Hansten and John
`Horn, Wolters Kluwer Health.
`2014 The Top 100 Drug Interactions: A Guide to Patient Management, 2014 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2013 The Top 100 Drug Interactions: A Guide to Patient Management, 2013 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2013 Drug Interactions Analysis and Management (Bound), Philip Hansten and John
`Horn, Wolters Kluwer Health.
`2012 The Top 100 Drug Interactions: A Guide to Patient Management, 2012 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2012 Drug Interactions Analysis and Management (Bound), Philip Hansten and John
`Horn, Wolters Kluwer Health.
`2011 Drug Interactions Analysis and Management (Bound), Philip Hansten and John
`Horn, Wolters Kluwer Health.
`2011 The Top 100 Drug Interactions: A Guide to Patient Management, 2011 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2010 Drug Interactions Analysis and Management (Bound), Philip Hansten and John
`Horn, Wolters Kluwer Health.
`2010 The Top 100 Drug Interactions: A Guide to Patient Management, 2010 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2009 Drug Interactions Analysis and Management (Bound), Philip Hansten and John
`Horn, Wolters Kluwer Health.
`2009 The Top 100 Drug Interactions: A Guide to Patient Management, 2009 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2008 Drug Interactions Analysis and Management (Bound), Philip Hansten and John
`Horn, Wolters Kluwer Health.
`2008 The Top 100 Drug Interactions: A Guide to Patient Management, 2008 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2007 Drug Interactions Analysis and Management (Bound), Philip Hansten and John
`Horn, Wolters Kluwer Health.
`2007 The Top 100 Drug Interactions: A Guide to Patient Management, 2007 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2006 Drug Interactions Analysis and Management (Bound), Philip Hansten and John
`Horn, Wolters Kluwer Health.
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`2006 The Top 100 Drug Interactions: A Guide to Patient Management, 2006 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2005 Hansten and Horn Managing Clinically Important Drug Interactions, Philip
`Hansten and John Horn, Facts and Comparisons, Inc.
`2005 The Top 100 Drug Interactions: A Guide to Patient Management, 2005 Edition,
`Philip Hansten and John Horn, H&H Publications
`2004 Hansten and Horn Managing Clinically Important Drug Interactions, Philip
`Hansten and John Horn, Facts and Comparisons, Inc.
`2004 The Top 100 Drug Interactions: A Guide to Patient Management, 2004 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2003 The Top 100 Drug Interactions: A Guide to Patient Management, 2003 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2002 Hansten and Horn Managing Clinically Important Drug Interactions, Philip
`Hansten and John Horn, Facts and Comparisons, Inc.
`2002 The Top 100 Drug Interactions: A Guide to Patient Management, 2002 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2001 The Top 100 Drug Interactions: A Guide to Patient Management, 2001 Edition,
`Philip Hansten and John Horn, H&H Publications.
`2000 The Top 100 Drug Interactions: A Guide to Patient Management, 2000 Edition,
`Philip Hansten and John Horn, H&H Publications.
`1999 The Top 100 Drug Interactions: A Guide to Patient Management, Philip Hansten
`and John Horn, H&H Publications.
`1999 Hansten and Horn’s Drug Interactions Analysis and Management, Philip Hansten
`and John Horn, Facts and Comparisons, Inc.
`1998 Hansten and Horn’s Managing Clinically Important Drug Interactions, Philip
`Hansten and John Horn, authors and editors, Applied Therapeutics, Inc.
`1997 Hansten and Horn’s Drug Interactions Analysis and Management, Philip Hansten
`and John Horn authors and editors, Applied Therapeutics, Inc.
`1997 Drug Interactions and Updates: 1996, Philip Hansten and John Horn, Applied
`Therapeutics, Inc. and Waverly, Inc.
`1993 Drug Interactions and Updates Quarterly, Philip Hansten and John Horn authors
`and editors, Lea and Febiger / Applied Therapeutics, Inc.
`1991 Drug Interactions and Updates, 7th Edition, Philip Hansten and John Horn
`authors and editors, Lea and Febiger / Applied Therapeutics, Inc.
`1989 Drug Interactions, 6th Edition, Philip Hansten and John Horn authors and editors,
`Lea and Febiger / Applied Therapeutics, Inc.
`
`
`Newsletters
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`1988 - 2000. Drug Interactions Newsletter and Updates, authored and edited by Philip
`Hansten and John Horn, published quarterly, Facts and Comparisons, Inc.
`1985 - 1987. Drug Interactions Newsletter and Updates, authored and edited by Philip
`Hansten and John Horn, published monthly, Applied Therapeutics, Inc.
`
`Book Chapters
`Horn JR. Important Drug Interactions and Their Mechanisms, in Basic and Clinical
`Pharmacology, by Katzung B, McGraw-Hill Companies, Inc., New York, NY, 13th
`edition, 2015.
`Horn JR. Important Drug Interactions and Their Mechanisms, in Basic and Clinical
`Pharmacology, by Katzung B, McGraw-Hill Companies, Inc., New York, NY, 12th
`edition, 2012.
`Horn JR. Cytochrome P450 Enzyme Interactions, in Clinical Drug Data, McGraw-Hill
`Companies, Inc., New York, NY, 11th edition, 2010.
`Horn JR. Important Drug Interactions and Their Mechanisms, in Basic and Clinical
`Pharmacology, by Katzung B, McGraw-Hill Companies, Inc., New York, NY, 11th
`edition, 2009.
`Horn JR. Important Drug Interactions and Their Mechanisms, in Basic and Clinical
`Pharmacology, by Katzung B, McGraw-Hill Companies, Inc., New York, NY, 10th
`edition, 2007.
`
`Peer-Reviewed Articles
`75. Hochheiser H, Yifan N, Hernandez A, Horn J, Jacobson R, Boyce R, A feasibility
`study of the use of non-experts for annotating pharmacokinetic drug-drug interaction
`mentions in product labeling. J Med Internet Resch. Accepted.
`74. Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Johann Stan J, Tatonetti N, Vilar S,
`Brochhausen M, Samwald M, Rastegar-Mojarad M, Dumontier M, Boyce RD. Toward a
`complete dataset of drug-drug interaction information from publicly available sources.
`Journal of Biomedical Informatics, accepted.
`73. Chan LC, Lin YS, Tay-Sontheimer JC, rawick D, Oelschlager BK, Flum DR, Patton
`KK, Shen DD, Horn JR. Proximal Roux-en-Y Gastric bypass alters the onset and rate of
`drug absorption without a significant change to the overall systemic exposure of
`CYP3A4 and P-glycoprotein substrates. Pharmacotherapy. 2015;35:361-9.
`72. Pfunder A, Schonberg T, Horn J, Boyce R, Samwald M. Utilizing the wikidata
`system to improve the quality of medical content in Wikipedia in diverse languages: a
`pilot study. J Med Internet Resch. 2015;17:1-11.
`71. Scheife R, Hines L, Boyce R, Chung S, Momper J, Sommer C, Abernethy D, Horn J,
`Sklar S, Wong S, Jones G, Brown M, Grizzle A, Comes S, Wilkins T, Borst C, Wittie M,
`Malone D. Consensus recommendations for systematic evaluation of drug-drug
`interaction evidence for clinical decision support. Drug Saf. 2015;38:197-206.
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`70. Wood MD, Delate T, Clark M, Clark N, Horn JR, Witt DM. An Evaluation of the
`potential drug interaction between warfarin and levothyroxine. J Thromb Haemost.
`2014;12:1-7.
`69. Shaver A, Horn J. Comparison of warfarin and acetaminophen drug-drug interaction
`warnings between prescription and OTC drug labels in acetaminophen-containing
`products. Pharmacotherapy. 2014;34:e100. Abstract.
`68. Boyce R, Horn J, Hassanzadeh O, de Waard A, Schneider J, Luciano J, Rastegar-
`Mojarad M and Liakata M. Dynamic Enhancement of Drug Product Labels to Support
`Drug Safety, Efficacy, and Effectiveness. J Biomed Semantics. 2013;4(1):5-26.
`67. Horn JR, Gumpper KF, Hardy JC, McConnell PJ, Phansalkar S, Reilly C. Clinical
`decision support for drug–drug interactions: Improvement needed. Am J Health-Syst
`Pharm. 2013; 70:905-9.
`66. Boyce R, Collins C, Clayton M, Horn J. Inhibitory Metabolic Drug Interactions with
`Newer Psychotropic Drugs: Inclusion in Package Inserts and Influences of Concurrence
`in Drug Interaction Screening Software, Annals of Pharmacotherapy. 2012 46:1287-
`1298.
`65. Horn JR, Mantione MM, Johanson JF. OTC Polyethylene Glycol 3350 and the
`Pharmacist’s Role in Managing Constipation, J Am Pharm Assoc, 2012;52:372–380.
`64. Horn JR, Hansten PD, Osborn JD, Wareham P, Somani S. Excess Drug-Drug
`Interaction Alerts: Customizing Clinical Decision Support Before Initiating CPOE. Am J
`Health-Sys Pharm. 2011;68:662-664.
`63. Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The Risk of Hypotension
`Following Co-prescription of Macrolide Antibiotics and Calcium Channel Blockers. Can
`Med Assoc J. 2011;183:303-7.
`62. Boyce R, Collins C, Horn J, Kalet I. Computing with Evidence Part II: An Evidential
`Approach to Predicting Metabolic Drug-drug Interactions. Journal of Biomedical
`Informatics, 2009;42:990-1003.
`61. Boyce R, Collins C, Horn J, Kalet I. Computing with Evidence Part I: A Drug-
`mechanism Evidence Taxonomy Oriented Toward Confidence Assignment. Journal of
`Biomedical Informatics, 2009;42:979-989.
`60. Frishman WH, Horn JR. Statin-Drug Interactions: Not a Class Effect. Cardiology in
`Review, 2008;16:205-12.
`59. Horn JR, Hansten PD, Chan L-N. Proposal for a New Tool to Evaluate Drug
`Interaction Cases. Ann Pharmacother. 2007;41:674-80.
`58. Boyce R, Collins C, Horn J, Kalet I. Modeling Drug Mechanism Knowledge Using
`Evidence and Truth Maintenance, IEEE Transactions on Information Technology in
`Biomedicine, 2007;11:386-397.
`57. Lafata JE, Simpkins J, Kaatz S, Horn JR, Raebel MA, Schultz L, Smith DH, Yood M,
`What Do Medical Records Tell Us About Potentially Harmful Co-Prescribing?, Joint
`Commission Journal on Quality and Patient Safety. 2007;33:395-400.
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`56. Horn JR. Understanding the Pharmacodynamic and Pharmacokinetic Differences
`Between Proton Pump Inhibitors: Focus on pKa and Metabolism, Aliment Pharmacol
`Ther Symp Series. 2006;2:340-50.
`55. Horn JR. Managing Constipation in Adults: Patient Counseling and Triage. U.S.
`Pharmacist. 2006;31:67-76.
`54. Lafata JE, Schultz L, Simpkins J, Chan KA, Horn JR, Kaatz S, Long C, Platt R,
`Raebel MA, Smith DH, Xi H, Yood M. Potential Drug-Drug Interactions in the Outpatient
`Setting. Medical Care. 2006;44:543-541.
`53. Boyce R, Collins C, Horn J, Kalett IJ. Qualitative Pharmacokinetic Modeling of
`Drugs. AMIA Ann Symp Proc. 2005;71-5.
`52. Horn JR, Howden CW. Review article: similarities and differences among delayed-
`release proton-pump inhibitor formulations. Aliment Pharmacol Ther. 2005;22(Suppl
`3):20-4.
`51. Horn J. Review Article: Relationship Between the Metabolism and Efficacy of Proton
`Pump Inhibitors – Focus on Rabeprazole. Aliment Pharmacol Therap. 2004;20(s6):11-
`19.
`50. Robinson M, Horn JR. The Clinical Pharmacology of Proton Pump Inhibitors: What
`the Practicing Physician Needs to Know, Drugs. 2003;63:2739-2754.
`49. Horn JR, Hulisz D. Pharmacist’s Role in Recognizing and Managing Patients with
`Irritable Bowel Syndrome, Pharmacy Times. 2003;69:55-63.
`48. Horn JR, Hansten PD. Drug Interactions: Answers to Frequently Asked Questions.
`Pharmacy Times. 2002;68:67-76.
`47. Hansten PD, Horn JR, Hazlet TK. ORCA: Operational Classification of Drug
`Interactions. J Am Pharm Assoc. 2001;41:161-5.
`46. Hazlet TK, Lee TA, Hansten PD, Horn, JR. Performance of Community Pharmacy
`Drug Interaction Software, J Am Pharm Assoc. 2001;41:200-4.
`45. Lill J, Bauer LA, Horn JR, Hansten PD. Cyclosporine-drug interactions and the
`influence of patient age. Am J Health-Syst Pharm. 2000;57:1579-84.
`44. Bauer LA, Horn JR, Maxon MS, Easterling TR, Shen DD, Strandness DE. Effect of
`Metoprolol and Verapamil Administered Separately and Concurrently after Single Doses
`on Liver Blood Flow and Drug Disposition. Journal of Clinical Pharmacology,
`2000;40:533-543.
`43. Lill JS, O’Sullivan T, Bauer LA, Horn JR, Carithers R, Strandness DE, Lau H, Chan
`K, Thakker K. Pharmacokinetics of Diclofenac Sodium in Chronic Active Hepatitis and
`Alcoholic Cirrhosis. Journal of Clinical Pharmacology. 2000.40:1-8.
`42. Horn JR. Proton Pump Inhibitors: Similarities and Differences. Clinical Therapeutics.
`2000;22:266-280.
`41. Harrington RD, Woodward JA, Hooten TM, Horn JR. Life-threatening interactions
`between HIV-1 protease inhibitors and gamma-hydroxybutyrate (GHB) and
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`methylenedioxymetamphetamine (MDMA). Archives of Internal Medicine.
`1999;159:2221-4.
`40. Horn JR. Cisapride Suspension in the Treatment of Gastrointestinal Motility
`Disorders, Nursing Home Medicine. 1997;5:364-9.
`39. Horn JR. Use of Prokinetic Agents in Special Populations. Am J Health System
`Pharmacy. 1996;53:S27-9
`38. Barnes AD, Horn JR, Wittkowsky AK. Lack of In Vitro Interaction Between Heparin
`and Nitroglycerin, Am J Clin Pathol. 1996:105;298-300.
`37. Bauer LA, Horn JR, Pettit H, “Mixed-Effect Modeling for Detection and Evaluation of
`Drug Interactions: Digoxin-Quinidine and Digoxin-Verapamil Drug Combinations”,
`Therapeutic Drug Monitoring. 1996;18:46-52.
`36. Horn JR. Hansten PD. Drug Interactions with Antibacterial Agents, J Family Prac.
`1995;41:81-90.
`35. Horn JR. Pharmacology of Over-The-Counter Analgesics Used for the Treatment of
`Headache, Headache.1994;34(Suppl 1):6-9.
`34. Horn JR. Pharmacology of Prokinetic Agents. Consult Pharmacist. 1994;9(Suppl
`A):32-35.
`33. Horn JR, Anderson GD. Stability of an Extemporaneously Compounded Cisapride
`Suspension, Clinical Therapeutics. 1994;2:169-172.
`32. Schmiedl U, Schmoll K, Horn J, Speck U, Freeny P. Imaging of Exocrine Pancreatic
`Function: Investigation of the Bioavailability of Weak Organic Acids as Potential
`Pancreatic Contrast Agents for Computerized Tomography. Invest Radiology,
`1994;29:689-94.
`31. Reiss WG, Bauer LA, Horn JR, Zierler BK, Easterling TR, Strandness DE, JR. The
`Acute Effects of Sublingual Nitroglycerin on Hepatic Blood Flow in Healthy Volunteers. J
`Clin Pharmacol. 1994;34:912-18.
`30. Bauer LA, O'Sullivan T, Reiss WG, Horn JR, Opheim K, Strandness DE, Carithers
`RL. Liver Blood Flow, Antipyrine Clearance and Antipyrine Metabolite Formation
`Clearance in Patients with Chronic Active Hepatitis and Alcoholic Cirrhosis. Br J Clin
`Pharmacol. 1994;37:375-381
`29. Clark WR, Horn JR, Kawabori I, Gurtel S. Potentially Serious Drug Interactions
`Secondary to High-Dose Diltiazem Used in the Treatment of Pulmonary Hypertension.
`Pharmacotherapy. 1993;13:402-5.
`28. Zierler BK, Kirkman TR, Kraiss LW, Reiss WG, Horn JR, Bauer LA, Clowes AW,
`Kohler TR. Accuracy of Duplex Scanning for Measurement of Arterial Volume Flow. J
`Vasc Surg. 1992;16:520-6.
`27. Bauer LA, Schumock G, Horn JR, Opheim K. Verapamil Inhibits Ethanol Elimination
`and Prolongs the Perception of Intoxication. Clin Pharmacol Ther. 1992;52:6.
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`26. Reiss WG, Bauer LA, Horn JR, Zierler BK, Easterling TR, Strandness DE. The
`Effects of Oral Nifedipine on Hepatic Blood Flow in Man. Clin Pharmacol Ther.
`1991;50:379-84.
`25. O'Sullivan TA, Bauer LA, Horn JR, Zierler BK, Strandness DE, Williams-Warren J,
`Smith AL, Unadkat JD. Disposition of Drugs in Cystic Fibrosis: II. Hepatic Blood Flow.
`Clin Pharmacol Ther. 1991;50:450-5.
`24. Zierler BK, Horn JR, Bauer LA, Reiss WG, Strandness DE. Hepatic Blood Flow
`Measurements By Duplex Ultrasound: How to Minimize Variability. J Vasc Technol.
`1991;15:16-22.
`23. Horn JR, Zierler B, Bauer LA, Reiss W, Strandness DE. Estimation of Hepatic Blood
`Flow in Branches of Hepatic Vessels Utilizing a Non-invasive, Duplex Doppler Method.
`J Clin Pharmacol. 1990;30:922-9.
`22. Bauer LA, McDonnell N, Horn JR, Zierler B, Opheim K, Strandness DE. Single and
`Multiple Doses of Oral Cimetidine Do Not Change Liver Blood Flow in Humans. Clin
`Pharmacol Ther. 1990;48:195-200.
`21. Reid LD, Horn JR, McKenna DA. Therapeutic Drug Monitoring Reduces Toxic Drug
`Reactions: A Meta-Analysis. Ther Drug Monit. 1990;12:72-8.
`20. Kradjan WA, Kobayashi KA, Bauer LA, Horn JR, Opheim KE, Wood FJ. Glipizide
`Pharmacokinetics: Effects of Age, Diabetes, and Multiple Dosing. J Clin Pharm.
`1989;29:1121-7.
`19. Bauer LA, Murray K, Horn JR, Opheim K, Olsen J. Influence of Nifedipine Therapy
`on Indocyanine Green and Oral Propranolol Pharmacokinetics. Eur J Clin Pharmacol.
`1989;37:257-60.
`18. Bauer LA, Horn JR, Opheim KE. Variability of Indocyanine Green Pharmacokinetics
`in Healthy Adults. Clin Pharm. 1989;8:54-5.
`17. Reid LD, McKenna DA, Horn JR. Meta-Analysis of Research on the Effect of Clinical
`Pharmacokinetic Services on Therapeutic Drug Monitoring. Am J Hosp Pharm.
`1989;46:945-51.
`16. Reid LD, McKenna DA, Horn JR. Effect of Therapeutic Drug Monitoring Services on
`the Number of Serum Drug Assays Ordered for Patients: A Meta-Analysis. Ther Drug
`Monit. 1989;11:253-63.
`15. Ellsworth AJ, Horn JR, Raisys VA, Miyagawa LA, Bell JL. Disopyramide and N-
`Monodesalkyl Disopyramide in Serum and Breast Milk. Drug Intell Clin Pharm.
`1989;23:56-7.
`14. Kobayashi K, Bauer L, Horn J, Opheim K, Wood F and Kradjan W. Glipizide
`Pharmacokinetics in Young and Elderly Volunteers. Clin Pharm. 1988;7:224-8.
`13. Arrigoni L, Fundak G, Horn J, Kradjan W, Ellsworth A, Opheim K, Taylor T, and
`Bauer L. Comparison of Chlorpropamide Pharmacokinetics in Young Normal Adults and
`Older Diabetic Patients. Clin Pharm. 1987;6:162-4.
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`12. Brown-Molnar CS, Bauer LA and Horn JR. Phenytoin Removal by Plasmapheresis
`in Renal Insufficiency. Am J of Nephrol. 1986;6:302-6.
`11. Bauer LA, Kradjan WA and Horn JR. Use of Computer Case Presentations to
`Review Clinical Pharmacokinetics During Clinical Clerkships. Am J Pharm Educ.
`1986;50:146-8.
`10. Bauer LA, Horn JR, Stenwall M et al. Changes in Antipyrine and Indocyanine Green
`Kinetics During Calcium Antagonist Therapy. Clin Pharmacol Ther. 1986;40:239-42.
`9. Mills GR and Horn JR. Beta Blockers and Glucose Control. Drug Intell Clin Pharm.
`l985;l9:246-51.
`8. Horn JR, Christensen DB and deBlaquiere PA. Evaluation of a Digoxin
`Pharmacokinetic Monitoring Service in a Community Hospital. Drug Intell Clin Pharm.
`l985;l9:45-52.
`7. Koup JR, Horn JR. Multiple Dose Nonlinear Regression Analysis Program for the
`Microcomputer. Ther Drug Monit. 1984;6:51-7.
`6. Danziger LH and Horn JR. Disopyramide Induced Urinary Retention: Report of Nine
`Cases and Review of the Literature. Arch Intern Med. 1983;143:1683-6.
`5. Horn JR, Rylander ML, Hicks H. Propranolol-Induced Hallucinosis. Clin Pharm.
`1982;1:464-8.
`4. Horn JR, Danziger L. Warfarin-Induced Skin Necrosis. Am J Hosp Pharm.
`1981;38:1763-8.
`3. Horn JR. Response Rates to Direct Reprint Requests. Am J Hosp Pharm.
`1979;36:1219-21.
`2. Horn JR, Hughes L. Disopyramide Dialysability. Lancet. 1978;2:214. (Letter).
`1. Guisti DL, Horn JR. The Pharmacokinetics of Flucytosine in Cryptococcal Meningitis.
`Drug Intell Clin Pharm. 1975;9:180-8.
`
`
`
`Other Scholarly Publications
`208. Horn JR, Hansten PD. Flibanserin: Hypotension and Syncope with Drug
`Interactions. Pharmacy Times. 2015;81(October):31.
`207. Horn JR, Hansten PD. Milk Thistle Drug Interactions. Pharmacy Times.
`2015;81(September):42.
`206. Horn JR, Hansten PD. Edoxaban: A New Oral Factor Xa Inhibitor Anticoagulant.
`Pharmacy Times. 2015;81(August):36.
`205. Horn JR, Hansten PD. Anticholinergic Drug Interactions. Pharmacy Times.
`2015;81(July):33.
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`204. Horn JR, Hansten PD. Drug-Disease Interactions. Pharmacy Times.
`2015;81(June):32.
`203. Horn JR, Hansten PD. Drug Interaction Information: Too Many “Cooks”?.
`Pharmacy Times. 2015;81(May):27.
`202. Horn JR, Hansten PD. Evaluation of Drug Interaction Reports: Drug Dosing.
`Pharmacy Times. 2015;81(April):34.
`201. Horn JR, Hansten PD. Warfarin Prescribed Despite Potentially Serious Interactions
`with Other Medications. Pharmacy Times. 2015;81(March):42.
`200. Horn JR, Hansten PD. Gastrointestinal Bleeding Due to Drug-Drug Interactions.
`Pharmacy Times. 2015;81(February):38.
`199. Horn JR, Hansten PD. Another Thiopurine-Allopurinol Tragedy. Pharmacy Times.
`2015;81(January):36.
`198. Horn JR, Hansten PD. Drug Interactions with Marijuana. Pharmacy Times.
`2014;80(December):36.
`197. Horn JR, Hansten PD. Codeine Drug Interactions. Pharmacy Times.
`2014;80(November):48.
`196. Horn JR, Hansten PD. Prediction of Potential Drug-Drug Interactions. Pharmacy
`Times. 2014;80(October):42.
`195. Horn JR, Hansten PD. Extrapolating Pharmacokinetic Data to the Clinical
`Situation. Pharmacy Times. 2014;80(September):44.
`194. Horn JR, Hansten PD. Interactions with Hepatitis C Antivirals. Pharmacy Times.
`2014;80(August):38.
`193. Horn JR, Hansten PD. Hyperkalemia from Drug Interactions: New Data. Pharmacy
`Times. 2014;80(July):42.
`192. Horn JR, Hansten PD. Statins and OATP Interactions. Pharmacy Times.
`2014;80(June):42.
`191. Horn JR, Hansten PD. Is Acetaminophen a Problem in Hypertensive Patients?
`Pharmacy Times. 2014;80(May):38.
`190. Horn JR, Hansten PD. Variability in Drug Interactions: Does a One-Size Dose
`Adjustment Fit All? Pharmacy Times. 2014;80(April):46.
`189. Horn JR, Hansten PD. Serotonin Syndrome: Myths and Misconceptions. Pharmacy
`Times. 2014;80(March):38.
`188. Horn JR, Hansten PD. Kinase Inhibitors: An Update. Pharmacy Times.
`2014;80(February):36.
`187. Horn JR, Hansten PD. Lomitapide Drug Interactions. Pharmacy Times.
`2014;80(January):36.
`
`AMN1004
`IPR of Patent No. 8,772,306
`
`

`
`186. Horn JR, Hansten PD. Carboxylesterases and Drug Interactions. Pharmacy Times.
`2013;79(December):32.
`185. Horn JR, Hansten PD. Incidence of Adverse Drug Interactions. Pharmacy Times.
`2013;79(November):34.
`184. Horn JR, Hansten PD. Apixaban: An Oral Anticoagulant. Pharmacy Times.
`2013;79(October):40.
`183. Horn JR, Hansten PD. Prescriber Response to Drug-Drug Interaction Alerts in
`High=Risk Patients: A Surprising Finding. Pharmacy Times. 2013;79(September):32.
`182. Horn JR, Hansten PD. Statins and Macrolide Antibiotics: Defining the Risk.
`Pharmacy Times. 2013;79(August):46.
`181. Horn JR, Hansten PD. Caffeine and Clozapine. Pharmacy Times.
`2013;79(July):33.
`180. Horn JR, Hansten PD. Beta-Blockers and Beta-Agonists: What is the Risk?
`Pharmacy Times. 2013;79(June):41.
`179. Horn JR, Hansten PD. Antiplatelet Effects of Aspirin: Which NSAIDs Interact?.
`Pharmacy Times. 2013;79(May):36.
`178. Horn JR, Hansten PD. Diuretics, ACEIs, ARBs and NSAIDs: A Nephrotoxic
`Combination. Pharmacy Times. 2013;79(April):40.
`177. Horn JR, Hansten PD. Warfarin and Levothyroxine Revisited. Pharmacy Times.
`2013;79(Mar):38.
`176. Horn JR, Hansten PD. Stribild® – A New Approach to Pharmacoenhancement.
`Pharmacy Times. 2013;79(Feb):48.
`175. Horn JR, Hansten PD. Rare But Serious Drug Interactions. Pharmacy Times.
`2013;79(Jan):45.
`174. Horn JR, Hansten PD. Why Can’t We Just Get